Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer

  • Authors:
    • Ning Yang
    • Chuanming Li
    • Xiao Han
    • Zhihua Feng
    • Feng Qiu
    • Junqing Han
  • View Affiliations

  • Published online on: August 28, 2020     https://doi.org/10.3892/ol.2020.12034
  • Article Number: 172
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Associations of metastasis-associated protein 1 (MTA1) expression with computed tomography (CT) features, pathology and prognosis of elderly patients with non‑small cell lung cancer (NSCLC), and its clinical significance were explored. A total of 98 elderly patients with NSCLC were selected and underwent CT examination. The expression of MTA1 in carcinoma tissues and para-carcinoma normal tissues was detected via immunohistochemistry, and its associations with CT features, pathology and prognosis were analyzed. The results manifested that the expression of MTA1 in carcinoma tissues was significantly higher than that in para-carcinoma normal tissues, and it was associated with the degree of differentiation, stage and lymph node metastasis (P<0.05). Besides, the high expression of MTA1 was also related to the spicule sign, pleural indentation and lymph node metastasis (P<0.05) as well as the CT perfusion parameter capillary permeability (PMB) (P<0.05), but not to blood volume (BV), blood flow (BF) or time to peak (TTP). Moreover, the patients with high expression of MTA1 had significantly shorter survival time and a remarkably lower 5-year survival rate than those with low expression of MTA1 (P<0.05). In conclusion, MTA1 plays a certain role in the occurrence and development of NSCLC in elderly patients and has an association with their prognosis, which can provide references for the treatment and prognosis of NSCLC, with important clinical significance.

Introduction

Lung cancer is the most common malignant tumor. The morbidity and mortality rates rank first among all malignant tumors, seriously threatening human health (1). Lung cancer includes small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the latter of which is dominant (2). The early clinical symptoms of NSCLC are atypical, so the patients are in the middle and advanced stage once diagnosed, with unsatisfactory efficacy and poor prognosis. In recent years, the efficacy of specific gene- or protein-targeted therapies for middle and advanced NSCLC has greatly improved. However, the prognosis of NSCLC is still very poor and the 5-year survival rate has not improved. Therefore, study on the prognostic factors of NSCLC would be helpful for effective judgment of the prognosis and the formulation of individualized treatment plan (3). Metastasis is the main cause of death of patients (4,5). Metastasis-associated protein 1 (MTA1) plays an important role in tumor metastasis and often serves as a potential indicator for malignant potential in clinic (6). Some studies have reported that MTA1 protein expression is associated with invasiveness, metastasis and clinical outcome in patients with NSCLC (79). Computed tomography (CT) examination is a conventional examination method for NSCLC, which can fully reflect the pathophysiological and molecular biological characteristics of tumors, and it has important value in guiding the diagnosis and therapeutic evaluation (10,11). However, the relationship between MTA1 protein expression and CT features has not been investigated so far. It was hypothesized that there was some correlation between the expression of MTA1 protein and CT features. Therefore, actively exploring the associations between the imaging features of NSCLC and molecular markers can provide a reliable theoretical basis for targeted therapy of NSCLC.

Patients and methods

General data

A total of 98 elderly patients with NSCLC treated in Shandong Provincial Hospital (Shandong, China) from July 2012 to June 2014 were selected. Inclusion criteria: i) Patients meeting the diagnostic criteria for NSCLC, ii) those undergoing CT examination, and iiii) those without mental disorders and receiving no surgery and chemoradiotherapy. Exclusion criteria: i) Patients with failure of major organs, such as heart, liver and kidney, ii) those with an allergic history of contrast agent, or iii) those who underwent drug therapy or surgical therapy previously (Table I).

Table I.

General data of patients.

Table I.

General data of patients.

CharacteristicsPatients
Total no.98
Mean age (years)68.74±5.86
Sex (male/female)69/29
Tissue type [n (%)]
  Squamous carcinoma53 (54.08)
  Adenocarcinoma45 (45.92)
Clinical stage [n (%)]
  I–II34 (34.69)
  III–IV64 (65.31)

The study was approved by the Ethics Committee of Shandong Provincial Hospital. Written informed consents were obtained from the patients and/or guardians.

CT examination

Before the examination, all patients underwent solid fasting for 6 h, and they were informed of relevant precautions. The patients removed any metal objects, raised both hands to place them on the both sides of the headrest. The dual-source CT machine (Siemens AG) was used for plain scan (tube voltage: 120 kV, rotation time: 0.5 sec, field of view: 414 mm, and slice thickness: 5 mm) from apex of the lung to costophrenic angle of patients under a supine position. Then the patients drank properly, and were injected with 50 ml of iohexol (350 mg/ml) at a rate of 6 ml/s using the automatic high-pressure injector also under the supine position. After injection for 7 sec, the perfusion scan was performed once per second for a total of 31 times under BODY PCT mode (tube current: 110 mAs, matrix: 512×512, collimation: 2×32×1.2 mm, rotation time: 0.28 sec, and tube voltage: 80 kV). Image analysis and processing: The scanning images were transferred to the processing workstation, and the clear perfusion slice with less moving artifact was analyzed and processed by software. Finally, the blood flow (BF), blood volume (BV), permeability surface (PS) and mean transit time (MTT) were calculated.

Detection of MTA1 expression

The expression of MTA1 in lung tissue specimens was determined using immunohistochemistry. The paraffin-embedded tissues were sliced into 4 μm-thick sections using a microtome (Leica Microsystems GmbH), baked at 60°C for 2 h, deparaffinized with xylene and soaked in gradient ethanol and distilled water for 5 min. Thereafter, the sections were added with 50 μl of 3% hydrogen peroxide solution, and incubated at 20°C for 10 min to block the activity of endogenous peroxidase. After washing with phosphate buffered saline (PBS) 3 times (5 min/time), the sections were incubated with 50 μl of primary antibodies MTA1 (1:300; cat. no. ab71153; Abcam) at 4°C overnight, and then incubated again with secondary antibodies (1:500; cat. no. ab7090; Abcam) at 20°C for 10 min, followed by color development using diaminobenzidine (DAB) kit (Beijing ZSGB Biotechnology Co., Ltd.), hematoxylin counterstaining for 2 min and sealing with neutral balsam.

Evaluation of indexes

Two senior radiologists conducted the imaging analysis. CT perfusion parameters included BV, BF, capillary permeability (PMB) and time to peak (TTP).

Expression of MTA1 in lung tissues determined using immu-nohistochemistry

Ten fields of view (magnification, ×200) were randomly selected in each section to detect the percentage of positive cells (brown yellow cells), and the percentage point (PP) was given: i) 0 point: no positive cells; ii) 1 point: percentage of positive cells <5%; iii) 2 points: >5% to ≤20% positive cells; iv) 3 points: percentage of positive cells >20%. Besides, the staining intensity (SI) was also scored: i) 0 point: no staining; ii) 1 point: light yellow; iii) 2 points: brown yellow; iv) 3 points: dark brown. Finally, the immunoreactivity score (IRS) was calculated: IRS = PPxSI. IRS >4 points indicates high expression, while IRS ≤4 points indicates low expression (12).

Statistical analysis

Statistical Product and Service Solutions (SPSS) 19.0 software (SPSS Inc., Chicago, IL, USA) was used for data processing. Measurement data were expressed as mean ± standard deviation (mean ± SD), and t-test was performed. Enumeration data were expressed as case (n) or percentage (%), and χ2 test was performed. P<0.05 indicates a statistically significant difference.

Results

Expression of MTA1 in carcinoma tissues and para-carcinoma normal tissues

As shown by immunohistochemistry in Fig. 1, the positive expression rate of MTA1 in 98 patients was 60.20% (59/98), and MTA1 was mainly expressed in the nucleus of carcinoma tissues. The positive expression of MTA1 was higher in poorly differentiated carcinoma than in moderately differentiated and well differentiated carcinoma, and the MTA1 expression was very low in para-carcinoma normal tissues.

Association between MTA1 and clinicopathological features of patients

The expression of MTA1 was associated with the degree of differentiation, stage and lymph node metastasis (P<0.05), but not with the age, sex or tissue type (P>0.05) (Table II).

Table II.

Association between MTA1 and clinicopathological features of patients [n (%)].

Table II.

Association between MTA1 and clinicopathological features of patients [n (%)].

ItemNo.High expression MTA1Low expression MTA1χ2P-value
Age, years
  <755533 (60.00)22 (40.00)0.0010.983
  ≥754325 (58.14)18 (41.86)
Sex
  Male6941 (59.42)28 (40.58)0.0230.879
  Female2917 (58.62)12 (41.38)
Tissue type
  Squamous carcinoma5331 (58.49)22 (41.51)0.0010.954
  Adenocarcinoma4527 (60.00)18 (40.00)
Degree of differentiation
  Well differentiated236 (26.09)17 (73.91)24.262<0.001
  Moderately differentiated3014 (46.67)16 (53.33)
  Poorly differentiated4538 (84.44)7 (15.56)
Lymph node metastasis
  +6351 (80.95)12 (19.05)32.127<0.001
  −357 (20.00)28 (80.00)
Clinical stage
  I–II349 (26.47)25 (73.53)21.037<0.001
  III–IV6449 (76.56)15 (23.44)
Association between CT image features and MTA1 expression

The expression of MTA1 was related to the spicule sign, pleural indentation sign and lymph node metastasis sign (P<0.05) (Table III).

Table III.

MTA1 expression in patients with different CT image features [n (%)].

Table III.

MTA1 expression in patients with different CT image features [n (%)].

CT image featuresNo.High expression MTA1Low expression MTA1χ2P-value
Lobulation sign8751 (58.62)36 (41.38)0.0010.994
No lobulation sign117 (63.64)4 (36.36)
Spicule sign6050 (83.33)10 (16.67)34.8240.983
No spicule sign388 (21.05)30 (78.95)
Pleural indentation sign6152 (85.25)9 (14.75)42.6170.983
No pleural indentation sign376 (16.22)31 (83.78)
Lymph node metastasis sign6351 (80.95)12 (19.05)21.037<0.001
No lymph node metastasis sign357 (20.00)28 (80.00)

[i] CT, computed tomography; MTA1, metastasis-associated protein 1.

Association between CT perfusion parameters and MTA1 expression

There were no obvious differences in BV, BF and TTP between MTA1 high expression group and MTA1 low expression group. PMB was higher in MTA1 high expression group than that in MTA1 low expression group (P<0.05) (Table IV).

Table IV.

Comparison of CT perfusion parameters in patients with different MTA1 expression.

Table IV.

Comparison of CT perfusion parameters in patients with different MTA1 expression.

GroupsNo.BF (ml•min-1•100g-1)BV (ml•100g-1)TTP (sec)PMB (ml•min-1•100g-1)
Low expression MTA14027.84±3.056.38±1.7224.78±3.1417.52±3.65
High expression MTA15828.18±3.526.59±1.8625.53±3.0232.48±3.15
t-test   0.41   0.28   0.8633.512
P-value >0.05>0.05>0.05<0.001

[i] CT, computed tomography; MTA1, metastasis-associated protein 1; BF, blood flow; BV, blood volume; TTP, time to peak; PMB permeability.

Survival status of patients with different MTA1 expression

Patients with low expression of MTA1 had significantly longer survival time and a remarkably higher 5-year survival rate than those with high expression of MTA1 (P<0.05) (Table V).

Table V.

Comparison of 5-year follow-up conditions between the groups.

Table V.

Comparison of 5-year follow-up conditions between the groups.

GroupsNo.5-year survival [n (%)]Mean survival time (months)
Low expression MTA14026 (65.00)59.85±7.38
High expression MTA15824 (41.38)44.52±6.63
χ2/t 4.3839.614
P-value 0.036<0.001

[i] MTA1, metastasis-associated protein 1.

Discussion

NSCLC is a malignant tumor originating from the bronchial mucous epithelium, its pathogenesis is not fully clear. It is generally believed that smoking, occupational carcinogens, air pollution, ionizing radiation, diet and nutrition, hereditary and genetic changes are the major precipitating factors, under the influence of which the carcinogens will cause damage to lung tissues. Due to the low immunity of the elderly, it is difficult for the self-defense and scavenging system of the body's immune mechanism to completely eliminate these carcinogens, so that the inflammatory response is induced, and abnormal changes are caused in the microenvironment of lungs, ultimately leading to the formation of malignant tumors (1315). Due to atypical early symptoms, NSCLC is usually diagnosed in the middle and advanced stage, during which the tumor is prone to metastasis and patients have poor prognosis (16).

MTA1 is a recently discovered protein associated with tumor metastasis, and it belongs to the tumor metastasis-associated protein family (17). Related studies have confirmed that the expression level of MTA1 is extremely low in normal tissues but obviously high in malignant tumor tissues, and it has a close association with tumor metastasis (18). In this study, the positive expression rate of MTA1 in 98 patients was 60.20% (59/98), and MTA1 was mainly expressed in the nucleus of carcinoma tissues. The positive expression of MTA1 was higher in poorly differentiated carcinoma than that in moderately differentiated and well differentiated carcinoma, and the MTA1 expression was very low in para-carcinoma normal tissues. This is because MTA1 can be detected in the nucleus of cancer tissues due to its high hydrophilicity and no transmembrane feature. In this study, the expression of MTA1 was associated with the degree of differentiation, stage and lymph node metastasis (P<0.05), but not with age, gender or tissue type (P>0.05). The reason is that MTA1 can inhibit ER gene transcription, thereby promoting down-regulation of ER expression, and facilitating the proliferation, invasion and metastasis of tumor cells, which make the prognosis of patients poorer and shorten their survival time.

CT examination has important value in the clinical diagnosis and treatment of NSCLC, characterized by clear images and short scanning time, and it is not influenced by surrounding tissues and organs (19). CT examination can be used to accurately observe the mass of NSCLC and to assess whether there is enlargement of lymph nodes and metastasis (20). With the development of imaging genomics, the NSCLC tissues can be quantitatively analyzed, so that the images can be converted into researchable data to reveal the intrinsic relation between tumor imaging features and molecular markers, which is of positive significance in predicting related gene mutations, and can offer strong support to targeted therapy of NSCLC (21). In this study, there was overexpression of MTA1 in tumor tissues in elderly NSCLC patients with spicule sign, pleural indentation sign and lymph node metastasis sign in CT images, indicating that patients with high expression of MTA1 are more prone to spicule sign, pleural indentation sign and lymph node metastasis sign. CT perfusion imaging technique can continuously scan the lesion area after high-pressure intravenous injection of contrast agent, thereby reflecting the hemodynamics of tumor tissues (22,23). In this study, there were no obvious differences in BV, BF and TTP between high expression MTA1 group and low expression MTA1 group. PMB was higher in high expression MTA1 group than that in low expression MTA1 group (P<0.05). The possible reason is that the overexpression of MTA1 will regulate the cell transcription level and affects tumor angiogenesis, but such a pro-angiogenic effect is not significant enough to alter the CT perfusion parameters BV, BF and TTP. However, in the case of MTA1 overexpression, the tumor is more prone to hematogenous metastasis, and PMB is obviously increased. As far as we know, MAT1 can only be detected in tissue, but not in the blood. In clinic, the lung tissues of patients were not always acquired for some reasons while CT examination was easy to obtain. The results of this study provide more evidence for targeted therapy of elderly NSCLC.

In conclusion, the expression of MTA1 has close associations with the CT features, pathology and prognosis of elderly NSCLC patients, which has positive guiding significance for targeted therapy of elderly with NSCLC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

NY, CL and JH designed the study and performed the experiments. NY, CL and XH acquired the data. ZF, XH and FQ analyzed the data. NY, CL and JH wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Shandong Provincial Hospital (Shandong, China). Written informed consents were obtained from the patients and/or guardians.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, et al TRACERx Consortium, : Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 376:2109–2121. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Liu L, Zhou XY, Zhang JQ, Wang GG, He J, Chen YY, Huang C, Li L and Li SQ: LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 22:8722–8730. 2018.PubMed/NCBI

3 

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, et al ALEX Trial Investigators, : Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 377:829–838. 2017. View Article : Google Scholar : PubMed/NCBI

4 

Rotow J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Hendriks LEL and Dingemans AC: Heat shock protein antagonists in early stage clinical trials for NSCLC. Expert Opin Investig Drugs. 26:541–550. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Ma K, Fan Y, Dong X, Dong D, Guo Y, Wei X, Ning J, Geng Q, Wang C, Hu Y, et al: MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer. Oncotarget. 8:38825–38840. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Zhu X, Guo Y, Li X, Ding Y and Chen L: Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer. J Thorac Oncol. 5:1159–1166. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G and Rubin MA: Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med. 130:989–996. 2006.PubMed/NCBI

9 

Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Yukiue H, Kaji M, Fukai I, Kiriyama M, Yamakawa Y and Fujii Y: Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer. 35:149–154. 2002. View Article : Google Scholar : PubMed/NCBI

10 

Swensen SJ: CT screening for lung cancer. AJR Am J Roentgenol. 179:833–836. 2002. View Article : Google Scholar : PubMed/NCBI

11 

Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, et al: CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials. Ann Oncol. 29:687–693. 2018. View Article : Google Scholar : PubMed/NCBI

12 

Jagadish N, Parashar D, Gupta N, Agarwal S, Sharma A, Fatima R, Suri V, Kumar R, Gupta A, Lohiya NK, et al: A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer. OncoImmunology. 5:e10789652016. View Article : Google Scholar : PubMed/NCBI

13 

Shi Y, Sun Y, Yu J, Ding C, Wang Z, Wang C, Wang D, Wang C, Wang Z, Wang M, et al: China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 Version). (In Chinese). View Article : Google Scholar

14 

Cui Y, Zhang F, Zhu C, Geng L, Tian T and Liu H: Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. Oncotarget. 8:17785–17794. 2017. View Article : Google Scholar : PubMed/NCBI

15 

Wang Q, Wang Q, Wang SF, Jiao LJ, Zhang RX, Zhong Y, Zhang J and Xu L: Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. Curr Oncol. 24:269–276. 2017. View Article : Google Scholar

16 

Vesel M, Rapp J, Feller D, Kiss E, Jaromi L, Meggyes M, Miskei G, Duga B, Smuk G, Laszlo T, et al: ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respir Res. 18:522017. View Article : Google Scholar : PubMed/NCBI

17 

Jia QP, Yan CY, Zheng XR, Pan X, Cao X and Cao L: Upregulation of MTA1 expression by human papillomavirus infection promotes CDDP resistance in cervical cancer cells via modulation of NF-κB/APOBEC3B cascade. Cancer Chemother Pharmacol. 83:625–637. 2019. View Article : Google Scholar : PubMed/NCBI

18 

Bui-Nguyen TM, Pakala SB, Sirigiri DR, Martin E, Murad F and Kumar R: Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein-HBx requires MTA1 coregulator. J Biol Chem. 292:47652017. View Article : Google Scholar : PubMed/NCBI

19 

Li HS, Lv RQ and Liu L: Correlation of CT indicators of NSCLC and pathological features and the expression level of p53 and c-myc. Eur Rev Med Pharmacol Sci. 22:135–141. 2018.PubMed/NCBI

20 

Lee J, Cui Y, Sun X, Li B, Wu J, Li D, Gensheimer MF, Loo BW Jr, Diehn M and Li R: Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC. Eur Radiol. 28:736–746. 2018. View Article : Google Scholar : PubMed/NCBI

21 

Abel S, Hasan S, White R, Schumacher L, Finley G, Colonias A and Wegner RE: Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma. Lung Cancer. 128:127–133. 2019. View Article : Google Scholar : PubMed/NCBI

22 

Carrascosa P and Capunay C: Myocardial CT perfusion imaging for ischemia detection. Cardiovasc Diagn Ther. 7:112–128. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Chu LL, Knebel RJ, Shay AD, Santos J, Badawi RD, Gandara DR and Knollmann FD: CT perfusion imaging of lung cancer: Benefit of motion correction for blood flow estimates. Eur Radiol. 28:5069–5075. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang N, Li C, Han X, Feng Z, Qiu F and Han J: Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer. Oncol Lett 20: 172, 2020.
APA
Yang, N., Li, C., Han, X., Feng, Z., Qiu, F., & Han, J. (2020). Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer. Oncology Letters, 20, 172. https://doi.org/10.3892/ol.2020.12034
MLA
Yang, N., Li, C., Han, X., Feng, Z., Qiu, F., Han, J."Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer". Oncology Letters 20.5 (2020): 172.
Chicago
Yang, N., Li, C., Han, X., Feng, Z., Qiu, F., Han, J."Associations of MTA1 expression with CT features, pathology and prognosis of elderly patients with non-small cell lung cancer". Oncology Letters 20, no. 5 (2020): 172. https://doi.org/10.3892/ol.2020.12034